Opiant Pharmaceuticals (OPNT) Earning Somewhat Favorable Media Coverage, Accern Reports
News articles about Opiant Pharmaceuticals (NASDAQ:OPNT) have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 45.5883755652857 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Opiant Pharmaceuticals in a report on Thursday, June 14th. ValuEngine lowered shares of Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 28th.
NASDAQ OPNT traded down $0.36 on Friday, hitting $22.65. 37,833 shares of the stock were exchanged, compared to its average volume of 39,263. Opiant Pharmaceuticals has a 52 week low of $12.75 and a 52 week high of $51.90. The firm has a market capitalization of $64.41 million, a P/E ratio of 7.70 and a beta of -0.04.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Read More: Stock Symbol
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.